Natarajan Ravendhran
About
Natarajan Ravendhran is a scholar working on Hepatology, Epidemiology and Infectious Diseases.
According to data from OpenAlex, Natarajan Ravendhran has authored 30 papers receiving a total of 923 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hepatology, 20 papers in Epidemiology and 9 papers in Infectious Diseases. Recurrent topics in Natarajan Ravendhran's work include Hepatitis C virus research (23 papers), Liver Disease Diagnosis and Treatment (15 papers) and Hepatitis B Virus Studies (10 papers). Natarajan Ravendhran is often cited by papers focused on Hepatitis C virus research (23 papers), Liver Disease Diagnosis and Treatment (15 papers) and Hepatitis B Virus Studies (10 papers). Natarajan Ravendhran collaborates with scholars based in United States, Germany and France. Natarajan Ravendhran's co-authors include Jonathan McCone, Ira M. Jacobson, Lorenzo Rossaro, Mitchell Davis, Joseph Galati, John M. Vierling, Frank Anderson, Paul Y. Kwo, Raymond A. Rubin and Eric Lawitz and has published in prestigious journals such as The Lancet, Gastroenterology and Hepatology.
In The Last Decade
Natarajan Ravendhran
29 papers receiving 900 citations
Hit Papers
Peers
Natarajan Ravendhran
Ewa Janczewska Poland
Kathryn Razavi‐Shearer United States
R. Soffredini Italy
Fernando E. Membreno United States
David Bernstein United States
Leif Bengtsson United States
Nai‐Jen Hou Taiwan
D. Hueppe Germany
Stephen Pianko Australia
Maissa El Raziky Egypt
Citations per year, relative to Natarajan Ravendhran Natarajan Ravendhran (= 1×)
peers
Ewa Janczewska
Countries citing papers authored by Natarajan Ravendhran
Since
Specialization
Citations
This map shows the geographic impact of Natarajan Ravendhran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Natarajan Ravendhran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Natarajan Ravendhran more than expected).
Fields of papers citing papers by Natarajan Ravendhran
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Natarajan Ravendhran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Natarajan Ravendhran. The network helps show where Natarajan Ravendhran may publish in the future.
Co-authorship network of co-authors of Natarajan Ravendhran
This figure shows the co-authorship network connecting the top 25 collaborators of Natarajan Ravendhran. A scholar is included among the top collaborators of Natarajan Ravendhran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Natarajan Ravendhran. Natarajan Ravendhran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Loomba, Rohit, Arun J. Sanyal, Atsushi Nakajima, et al.. (2023). Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study. Clinical Gastroenterology and Hepatology. 22(1). 102–112.e9.
2.
Flamm, Steven L., Eric Lawitz, Brian B. Borg, et al.. (2023). Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis. Viruses. 15(10). 2026–2026.
3.
Younossi, Zobair M., Naim Alkhouri, Fasiha Kanwal, et al.. (2022). A practical use of noninvasive tests in clinical practice to identify high‐risk patients with nonalcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics. 57(3). 304–312.
4.
Fashanu, Oluwaseun E., et al.. (2022). Association between body mass index and liver stiffness measurement using transient elastography in patients with non-alcoholic fatty liver disease in a hepatology clinic: a cross sectional study. Translational Gastroenterology and Hepatology. 8. 10–10.
5.
Poordad, Fred, Shahriar Sedghi, Paul J. Pockros, et al.. (2019). Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low‐dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis. Journal of Viral Hepatitis. 26(8). 1027–1030.
6.
Zuckerman, Eli, Julio Gutiérrez, Andrew Ustianowski, et al.. (2019). THU-198-Efficacy and safety of glecaprevir/pibrentasvir treatment for 8 weeks in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis: Analysis of data pooled from phase 2 and 3 studies. Journal of Hepatology. 70(1). e251–e251.
7.
Flamm, Steven L., Eric Lawitz, Brian B. Borg, et al.. (2019). THU-138-High efficacy and improvement in CPT class with sofosbuvir/velpatasvir plus ribavirin for 12 weeks in patients with CPT C decompensated cirrhosis. Journal of Hepatology. 70(1). e221–e222.
8.
Flamm, Steven L., Eric Lawitz, Brian B. Borg, et al.. (2019). 953 – High Efficacy and Improvement in Cpt Class with Sofosbuvir/Velpatasvir Plus Ribavirin for 12 Weeks in Patients with Cpt C Decompensated Cirrhosis. Gastroenterology. 156(6). S–1219.
9.
Gutiérrez, Julio, Eli Zuckerman, Andrew Ustianowski, et al.. (2019). 951 – Efficacy and Safety of Glecaprevir/Pibrentasvir Treatment for 8 Weeks in Treatment-Naïve Patients with Chronic Hepatitis C Virus Infection Without Cirrhosis Or with Compensated Cirrhosis: Analysis of Data Pooled from Phase 2 and 3 Studies. Gastroenterology. 156(6). S–1218.
10.
Bourlière, Marc, Stuart C. Gordon, Eugene R. Schiff, et al.. (2018). Deferred treatment with sofosbuvir–velpatasvir–voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. The Lancet. Gastroenterology & hepatology. 3(8). 559–565.
11.
Zamor, Philippe J., John M. Vierling, Reem Ghalib, et al.. (2018). Elbasvir/Grazoprevir in Black Adults With Hepatitis C Virus Infection: A Pooled Analysis of Phase 2/3 clinical Trials. The American Journal of Gastroenterology. 113(6). 863–871.
12.
Younossi, Zobair M., J. Santoro, Flavia Mendes, et al.. (2016). Implementation of baby boomer hepatitis C screening and linking to care in gastroenterology practices: a multi-center pilot study. BMC Gastroenterology. 16(1). 45–45.
13.
Kowdley, Kris V., Daniel Nelson, Jacob Lalezari, et al.. (2015). P0829 : On-treatment HCVRNA as a predictor of sustained virologic response in HCV genotype 3 infected patients treated with daclatasvir and sofosbuvir: analysis of phase 3 ALLY-3 study. Journal of Hepatology. 62. S648–S648.
14.
Wilder, Julius, Lennox J. Jeffers, Natarajan Ravendhran, et al.. (2015). Safety and efficacy of ledipasvir‐sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. Hepatology. 63(2). 437–444.
15.
Kowdley, Kris V., David R. Nelson, Jacob Lalezari, et al.. (2015). Tu1013 On-Treatment HCV RNA As a Predictor of Sustained Virologie Response in HCV Genotype 3 - Infected Patients Treated With Daclatasvir and Sofosbuvir: Analysis of Phase 3 Ally-3 Study. Gastroenterology. 148(4). S–1084.
16.
Tatum, H., Paul J. Thuluvath, E. Läwitz, et al.. (2012). 1163 A PHASE 2A STUDY OF BMS-791325, AN NS5B POLYMERASE INHIBITOR, WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION. Journal of Hepatology. 56. S460–S460.
17.
Melia, Michael T., Andrew J. Muir, Jonathan McCone, et al.. (2011). Racial differences in hepatitis C treatment eligibility. Hepatology. 54(1). 70–78.
18.
Kwo, Paul Y., Eric Lawitz, Jonathan McCone, et al.. (2010). Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. The Lancet. 376(9742). 705–716.
19.
Kwo, Paul Y., E. Läwitz, Jonathan McCone, et al.. (2008). 995 INTERIM RESULTS FROM HCV SPRINT-1: RVR/EVR FROM PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRONTM (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE-1 CHC. Journal of Hepatology. 48. S372–S372.
20.
Ravendhran, Natarajan, et al.. (2002). Endoscopic treatment of a post-traumatic biliary stricture mimicking a Klatskin tumor. Gastrointestinal Endoscopy. 55(2). 274–276.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ewa Janczewska Breakdown of academic impact, for papers by Kathryn Razavi‐Shearer Breakdown of academic impact, for papers by R. Soffredini Breakdown of academic impact, for papers by Fernando E. Membreno Breakdown of academic impact, for papers by David Bernstein Breakdown of academic impact, for papers by Leif Bengtsson Breakdown of academic impact, for papers by Nai‐Jen Hou Breakdown of academic impact, for papers by D. Hueppe Breakdown of academic impact, for papers by Stephen Pianko Breakdown of academic impact, for papers by Maissa El Raziky